<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00494299</url>
  </required_header>
  <id_info>
    <org_study_id>11721</org_study_id>
    <nct_id>NCT00494299</nct_id>
  </id_info>
  <brief_title>Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)</brief_title>
  <official_title>Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Progression (TTP)</measure>
    <time_frame>From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months.</time_frame>
    <description>Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From randomization of the first subject until 39 months later.</time_frame>
    <description>Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at their last date of follow-up were censored at the time of analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar, BAY43-9006)</intervention_name>
    <description>Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib</description>
    <arm_group_label>Sorafenib (Nexavar, BAY43-9006)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female

          -  Aged of 18 and over

          -  Advanced hepatocellular carcinoma

        Exclusion Criteria:

          -  History of prior systemic chemotherapy

          -  Failure in vital organ
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>460-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsuyama</city>
        <state>Ehime</state>
        <zip>791-0280</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toon</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iizuka</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>802-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitakyushu</city>
        <state>Fukuoka</state>
        <zip>807-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isesaki</city>
        <state>Gunma</state>
        <zip>372-0817</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kure</city>
        <state>Hiroshima</state>
        <zip>737-0193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>003-0804</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-0033</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akashi</city>
        <state>Hyogo</state>
        <zip>673-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <zip>650-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kasama</city>
        <state>Ibaraki</state>
        <zip>309-1793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920-8641</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Isehara</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <zip>228-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <zip>245-8575</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>983-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matsumoto</city>
        <state>Nagano</state>
        <zip>390-8621</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omura</city>
        <state>Nagasaki</state>
        <zip>856-8562</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>586-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moriguchi</city>
        <state>Osaka</state>
        <zip>570-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osakasayama</city>
        <state>Osaka</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izunokuni</city>
        <state>Shizuoka</state>
        <zip>410-2295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunto</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimotsuke</city>
        <state>Tochigi</state>
        <zip>329-0498</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>152-8902</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8470</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Musashino</city>
        <state>Tokyo</state>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nerima-ku</city>
        <state>Tokyo</state>
        <zip>177-8521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yonago</city>
        <state>Tottori</state>
        <zip>683-8504</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimonoseki</city>
        <state>Yamaguchi</state>
        <zip>750-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ube</city>
        <state>Yamaguchi</state>
        <zip>755-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chuo</city>
        <state>Yamanashi</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukui</city>
        <zip>918-8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu</city>
        <zip>500-8513</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>730-8619</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>734-8530</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hiroshima</city>
        <zip>734-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <zip>890-0061</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <zip>892-8512</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>860-0008</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>860-8556</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <zip>880-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <zip>700-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>530-8480</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>537-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>543-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>545-8586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <zip>558-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <zip>930-8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamagata</city>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <results_reference>
    <citation>Kudo M, Imanaka K, Chida N, Nakachi K, Tak WY, Takayama T, Yoon JH, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011 Sep;47(14):2117-27. doi: 10.1016/j.ejca.2011.05.007.</citation>
    <PMID>21664811</PMID>
  </results_reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 28, 2007</study_first_submitted>
  <study_first_submitted_qc>June 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2007</study_first_posted>
  <results_first_submitted>December 21, 2010</results_first_submitted>
  <results_first_submitted_qc>December 21, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2011</results_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Cancer</keyword>
  <keyword>Liver Cancer</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 27 Aug 2006. The final data collection date for the primary endpoint analysis was 10 Jul 2009. The study was conducted at 77 centers from 2 countries: Korea (7 centers) and Japan (70). 76 centers enrolled at least 1 subject (7 centers in Korea and 69 in Japan). The last subject's last visit occurred on 19 Nov 2010.</recruitment_details>
      <pre_assignment_details>Of 552 subjects screened, 458 were randomized and were valid for the efficacy analyses (intent to treat [ITT] population), and 456 received at least 1 dose of study drug and were valid for the safety analyses. 229 subjects were randomized to each group (sorafenib or placebo).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="227"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="229"/>
                <participants group_id="P2" count="229"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease Progression, Recurrence/Relapse</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="185"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Did Not Take Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Driven Decision Point</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="229"/>
            <count group_id="B2" value="229"/>
            <count group_id="B3" value="458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="8.7"/>
                    <measurement group_id="B2" value="68.1" spread="8.8"/>
                    <measurement group_id="B3" value="67.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="168"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Child Pugh Status</title>
          <description>A Child-Pugh (CP) score (determined by encephalopathy grade, ascites, serum bilirubin and albumin, prothrombin time) is used to assess the prognosis of chronic liver disease, mainly cirrhosis. One of the inclusion criterion for this study was a CP class A (good operative risk); class B (moderate risk) score or class C (poor operative risk) was excluded.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Status A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="229"/>
                    <measurement group_id="B3" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Status B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group (ECOG) performance status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status is a scale that measures how cancer affects a patient. 0 = fully active, 1 = restricted strenuous activity, 2 = ambulatory, 3 = limited selfcare, 4 = completely disabled, 5 = dead. Subjects entering this study must have had an ECOG score of 0 or 1.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="201"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Responder group to transcatheter arterial chemoembolization (TACE)</title>
          <description>Responder Group A: percentage of tumor necrosis or tumor shrinkage is 100 percentage. Responder Group B: percentage of tumor necrosis or tumor shrinkage is 25 percentage or more to less than 100 percentage. Subjects entering this study is a responder to TACE.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Responder Group A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responder Group B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Prior transcatheter arterial chemoembolization (TACE)</title>
          <description>Subjects entering this study must have had previous TACE at a maximum of 2 times.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="148"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="81"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Progression (TTP)</title>
        <description>Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation.</description>
        <time_frame>From randomization of the first subject until radiological progression or recurrence whichever came first, assessed up to 39 months.</time_frame>
        <population>Intention to treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP)</title>
          <description>Time to progression (TTP) was defined as the time from date of randomization to radiological progression / recurrence. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation.</description>
          <population>Intention to treat (ITT) population.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164" lower_limit="116" upper_limit="220"/>
                    <measurement group_id="O2" value="112" lower_limit="106" upper_limit="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Log Rank</param_type>
            <param_value>0.25204620</param_value>
            <estimate_desc>The comparison between the 2 groups is done using the log rank test stratified by the response of TACE (Responder group A versus Responder group B), ECOG performance status (PS) (0 versus 1) and the number of prior TACE (1 versus 2).</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.8735</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.6972</ci_lower_limit>
            <ci_upper_limit>1.0942</ci_upper_limit>
            <estimate_desc>Hazard Ratio: Sorafenib/Placebo.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at their last date of follow-up were censored at the time of analysis.</description>
        <time_frame>From randomization of the first subject until 39 months later.</time_frame>
        <population>Median overall survival (OS) and 95% Confidence interval (CI) were not estimable in Placebo Group and Upper Limit of 95% CI was not in Sorafenib Group because of more than half (188 for Placebo,186 for Sorafenib) of the individual study populations censored. Number of death is shown in &quot;Post-Hoc Outcome Measure&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at their last date of follow-up were censored at the time of analysis.</description>
          <population>Median overall survival (OS) and 95% Confidence interval (CI) were not estimable in Placebo Group and Upper Limit of 95% CI was not in Sorafenib Group because of more than half (188 for Placebo,186 for Sorafenib) of the individual study populations censored. Number of death is shown in &quot;Post-Hoc Outcome Measure&quot;.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Number of Death Cases Due to Any Cause</title>
        <time_frame>From randomization of the first subject until death due to any cause assessed up to 55 months.</time_frame>
        <population>Intention to treat (ITT) population. &quot;Overall Survival&quot; is shown in &quot;Secondary Outcome Measure: Overall Survival&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Sorafenib (Nexavar, BAY43-9006)</title>
            <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Death Cases Due to Any Cause</title>
          <population>Intention to treat (ITT) population. &quot;Overall Survival&quot; is shown in &quot;Secondary Outcome Measure: Overall Survival&quot;.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="229"/>
                <count group_id="O2" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>up to 39 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>up to 55 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Acronyms in Adverse Event section: - Absolute Neutrophil Count (ANC) - Alanine Transaminase (ALT) - Aspartate Transaminase (AST) - Atrioventricular (AV) - Central Nervous System (CNS) - Gastrointestinal (GI) - International Normalized Ratio (INR) - Not Otherwise Specified (NOS)</desc>
      <group_list>
        <group group_id="E1">
          <title>Sorafenib (Nexavar, BAY43-9006)</title>
          <description>Sorafenib (Nexavar, BAY43-9006) administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid) (morning and evening, every 12 hours as far as possible); Dose modification (delayed or reduced) was permitted due to toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Sorafenib (Nexavar, BAY43-9006) matching placebo (2 placebo tablets) orally administered bid (twice daily).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>NCI-CTCAE v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHILS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMOGLOBIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>INR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>EDEMA: LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CONDUCTION ABNORMALITY, AV BLOCK-3RD DEGREE (COMPLETE AV BLOCK)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>CARDIAC ISCHEMIA/INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HYPERTHYROIDISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>GI - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, BACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, ABDOMEN NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>LIVER DYSFUNCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEPATOBILIARY - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION (DOCUMENTED CLINICALLY), LUNG (PNEUMONIA)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC, BLOOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC, BILIARY TREE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC, LIVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC, LUNG (PNEUMONIA)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>INFECTION WITH NORMAL ANC, SKIN (CELLULITIS)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>AMYLASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>BILIRUBIN (HYPERBILIRUBINEMIA)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HYPOGLYCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>LIPASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>METABOLIC/LAB - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS ISCHEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>ENCEPHALOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>MOOD ALTERATION, DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>SYNCOPE (FAINTING)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>HAND-FOOT SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CNS HEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, ABDOMEN NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, COLON</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, ESOPHAGUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, VARICES (ESOPHAGEAL)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, STOMACH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, LIVER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEMORRHAGE, GI, LOWER GI NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>ARTERY INJURY, AORTA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>VASCULAR - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>THROMBOSIS/THROMBUS/EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>NCI-CTCAE v.3.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="229" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="193" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPHILS</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PLATELETS</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>LEUKOCYTES</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>EDEMA: LIMB</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DIARRHEA</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HEARTBURN</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>MUCOSITIS (FUNCTIONAL/SYMPTOMATIC), ORAL CAVITY</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>MUCOSITIS (CLINICAL EXAM), ORAL CAVITY</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FEVER</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>WEIGHT GAIN</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>WEIGHT LOSS</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, BACK</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, EXTREMITY-LIMB</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, ABDOMEN NOS</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, HEAD/HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PAIN, JOINT</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>FLU-LIKE SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>INFECTION - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ALKALINE PHOSPHATASE</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>AMYLASE</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>BILIRUBIN (HYPERBILIRUBINEMIA)</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HYPERGLYCEMIA</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINEMIA</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>LIPASE</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATEMIA</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>METABOLIC/LAB - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PROTEINURIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>MUSCULOSKELETAL - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUROPATHY: SENSORY</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>VOICE CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>HAND-FOOT SKIN REACTION</sub_title>
                <counts group_id="E1" subjects_affected="188" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>DERMATOLOGY - OTHER (SPECIFY)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="227"/>
              </event>
              <event>
                <sub_title>RASH/DESQUAMATION</sub_title>
                <counts group_id="E1" subjects_affected="99" subjects_at_risk="229"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="227"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>Bayer HealthCare AG</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

